Patents by Inventor Richard Jove

Richard Jove has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
    Publication number: 20230193258
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Application
    Filed: November 24, 2021
    Publication date: June 22, 2023
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • INDIRUBIN DERIVATIVES, AND USES THEREOF
    Publication number: 20230174483
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Application
    Filed: December 12, 2022
    Publication date: June 8, 2023
    Applicants: CITY OF HOPE, THE NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
    Inventors: Sangkil NAM, Richard JOVE, Leandros SKALTSOUNIS
  • Indirubin derivatives, and uses thereof
    Patent number: 11524937
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: December 13, 2022
    Assignees: City of Hope, The National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, Richard Jove, Leandros Skaltsounis
  • 5-BROMO-INDIRUBINS
    Publication number: 20220274964
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 1, 2022
    Inventors: Richard JOVE, Sangkil NAM, David HORNE, Jun XIE, Alexios Leandros SKALTSOUNIS, Marina KRITSANIDA, Nicolas GABORIAUD-KOLAR
  • 5-bromo-indirubins
    Patent number: 11306072
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 19, 2022
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Methods and compositions for the treatment of cancer or other diseases
    Patent number: 11208654
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: December 28, 2021
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • 5-BROMO-INDIRUBINS
    Publication number: 20200283421
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 10, 2020
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • INDIRUBIN DERIVATIVES, AND USES THEREOF
    Publication number: 20200247750
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Application
    Filed: October 7, 2019
    Publication date: August 6, 2020
    Inventors: Sangkil NAM, Richard JOVE, Leandros SKALTSOUNIS
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
    Publication number: 20200032255
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 30, 2020
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • Indirubin derivatives, and uses thereof
    Patent number: 10435367
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 8, 2019
    Assignees: City of Hope, The National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, Richard Jove, Leandros Skaltsounis
  • Methods and compositions for the treatment of cancer or other diseases
    Patent number: 10253318
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: April 9, 2019
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • ETP derivatives
    Patent number: 10246471
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 2, 2019
    Assignees: City of Hope, The Regents of the University of California
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • 5-BROMO-INDIRUBINS
    Publication number: 20180170915
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • ETP DERIVATIVES
    Publication number: 20180155367
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Application
    Filed: October 27, 2017
    Publication date: June 7, 2018
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • ETP derivatives
    Patent number: 9856273
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 2, 2018
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof
    Patent number: 9828342
    Abstract: One aspect of the invention relates to novel isatin derivative compounds and the pharmaceutical composition thereof. Another aspect of the invention relates to methods of using the isatin derivative compounds disclosed herein and the pharmaceutical compositions thereof. In certain embodiments, the method is used to treat a cancer or a tumor in a subject including, without limitation, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, and lymphoma. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the activation of one or more proteins such as EGFR, Erk1/2, Her2/Neu, Jak2, Src, Stat3, Akt, Cyclin B1, and Cdc25C. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the disruption of microtubule formations.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: November 28, 2017
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David A. Horne, Richard Jove, Christopher Lincoln, Sangkil Nam, Larry Overman, Jun Xie
  • Methods and compositions for the treatment of cancer or other diseases
    Patent number: 9688982
    Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 27, 2017
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
  • ETP DERIVATIVES
    Publication number: 20170037058
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 9, 2017
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Home, Richard Jove, Jun Xie, Claudia Kowolik
  • ETP derivatives
    Patent number: 9527868
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 27, 2016
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Larry Eugene Overman, Marcus Baumann, Sangkil Nam, David Horne, Richard Jove, Jun Xie, Claudia Kowolik
  • Indirubin derivatives and uses thereof in treating chronic myelogenous leukemia
    Patent number: 9512076
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). One aspect of the invention relates to a method of treating CML using at least one indirubin derivative compound or a pharmaceutical composition thereof. Indirubin derivatives (IRDs) potently inhibited Signal Transducer and Activator of Transcription 5 (Stat5) protein in CML cells. Compound IRD 810 inhibits Bcr-Abl/Stat5 or Src/Stat5 signaling in human KCL-22 CML and imatinib-resistant human KCL-22 CML cells expressing the T315I mutant Bcr-Abl. Previous studies indicate that SFKs cooperate with Bcr-Abl to activate downstream Stat5 signaling. Activation of Stat5 was strongly blocked by IRD 810 in CML cells. IRDs disclosed herein have been identified as potent inhibitors of Bcr-Abl/Stat5 or SFK/Stat5 signaling pathway.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: December 6, 2016
    Assignee: CITY OF HOPE
    Inventors: Richard Jove, Sangkil Nam, Alexios-Leandros Skaltsounis